59 related articles for article (PubMed ID: 38438374)
1. Anti-lung cancer synergy of low-dose doxorubicin and PD-L1 blocker co-delivered via mild photothermia-responsive black phosphorus.
Xu HZ; Chen FX; Li K; Zhang Q; Han N; Li TF; Xu YH; Chen Y; Chen X
Drug Deliv Transl Res; 2024 Apr; ():. PubMed ID: 38597996
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
Yang T; Kong Z; Ma W
Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
[TBL] [Abstract][Full Text] [Related]
4. Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma.
Yang X; Wang W; Ji T
Cell Death Dis; 2024 Mar; 15(3):186. PubMed ID: 38438374
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
6. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.
Ashizawa T; Iizuka A; Tanaka E; Kondou R; Miyata H; Maeda C; Sugino T; Yamaguchi K; Ando T; Ishikawa Y; Ito M; Akiyama Y
Biomed Res; 2019; 40(6):243-250. PubMed ID: 31839668
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
[TBL] [Abstract][Full Text] [Related]
9. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between arginine, glutamine, and the branched chain amino acid metabolism in the tumor microenvironment.
Wetzel TJ; Erfan SC; Figueroa LD; Wheeler LM; Ananieva EA
Front Oncol; 2023; 13():1186539. PubMed ID: 37274280
[TBL] [Abstract][Full Text] [Related]
11. BMS-202, a PD-1/PD-L1 inhibitor, decelerates the pro-fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways.
Cai Y; Xiao M; Li X; Zhou S; Sun Y; Yu W; Zhao T
Immun Inflamm Dis; 2022 Oct; 10(10):e693. PubMed ID: 36169254
[TBL] [Abstract][Full Text] [Related]
12. Nutritional Interventions to Improve Cachexia Outcomes in Cancer-A Systematic Review.
Braha A; Albai A; Timar B; Negru Ș; Sorin S; Roman D; Popovici D
Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888685
[No Abstract] [Full Text] [Related]
13. Polyene Phosphatidylcholine Ameliorates High Fat Diet-Induced Non-alcoholic Fatty Liver Disease
Lu Y; Feng T; Zhao J; Jiang P; Xu D; Zhou M; Dai M; Wu J; Sun F; Yang X; Lin Q; Pan W
Front Physiol; 2022; 13():810143. PubMed ID: 35295576
[TBL] [Abstract][Full Text] [Related]
14. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease.
Horgusluoglu E; Neff R; Song WM; Wang M; Wang Q; Arnold M; Krumsiek J; Galindo-Prieto B; Ming C; Nho K; Kastenmüller G; Han X; Baillie R; Zeng Q; Andrews S; Cheng H; Hao K; Goate A; Bennett DA; Saykin AJ; Kaddurah-Daouk R; Zhang B; ;
Alzheimers Dement; 2022 Jun; 18(6):1260-1278. PubMed ID: 34757660
[TBL] [Abstract][Full Text] [Related]
15. The PD-1/PD-L1 binding inhibitor BMS-202 suppresses the synthesis and secretion of gonadotropins and enhances apoptosis via p38 MAPK signaling pathway.
Jiang Y; Zhang J; Qiu J; Cui S
Drug Dev Res; 2022 Feb; 83(1):176-183. PubMed ID: 34309063
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
